Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:59:19 2026-02-09 pm EST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

Jan. 07	Tenth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
Nov. 20	Ninth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI

Baudax Bio, Inc. announced that it expects to receive $50 million in funding from Alumni Capital LP

Published on 08/22/2023

S&P Capital IQ

BAUDAX BIO, INC.

0.00%

Baudax Bio, Inc. announced that it has entered into a share purchase agreement for the gross proceeds of $50 million on August 23, 2023. The transaction will include participation from new investor, Alumni Capital LP.

Latest news about Baudax Bio, Inc.

Jan. 07	Tenth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
Nov. 20	Ninth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
25-10-03	Eighth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
25-08-08	Seventh Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
25-06-12	Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
25-04-04	Fifth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
25-01-16	Fourth Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
24-12-11	Motion for Case Conversion Filed by Baudax Bio, Inc.	CI
24-12-04	Third Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
24-10-03	Second Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
24-07-31	First Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.	CI
24-06-17	First Motion for Exclusivity Period Extension Filed by Baudax Bio, Inc.	CI
24-02-22	Baudax Bio, Inc. Filed for Bankruptcy	CI
23-11-20	Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-11-20	Baudax Bio, Inc.(OTCPK:BXRX) dropped from S&P TMI Index	CI
23-11-16	Baudax Bio, Inc.(OTCPK:BXRX) dropped from NASDAQ Composite Index	CI
23-10-18	Baudax Bio, Inc. to Initiate TI-168 Clinical Development	CI
23-10-06	Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	MT
23-10-06	Sector Update: Health Care Stocks Higher in Afternoon Trading	MT
23-10-06	Baudax Bio Appoints Natalie McAndrew as Interim Finance Chief	MT
23-10-06	Baudax Bio, Inc. Announces Board Changes	CI
23-10-06	Baudax Bio, Inc. Announces Chief Financial Officer Changes	CI
23-09-29	Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	MT
23-09-29	Top Premarket Decliners	MT
23-09-29	Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors	CI

Chart Baudax Bio, Inc.

Duration

Period

BXRXQ: Dynamic Chart

Company Profile

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company